{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:02:49Z","timestamp":1756339369228,"version":"3.44.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,27]]},"DOI":"10.7759\/cureus.91082","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:25:24Z","timestamp":1756279524000},"source":"Crossref","is-referenced-by-count":0,"title":["Hypercalcemia of Malignancy and Medication-Related Osteonecrosis of the Jaw Following Denosumab Discontinuation in Metastatic Breast Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Omar","family":"Shazley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Orr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00293","article-title":"Calcium homeostasis: a potential vicious cycle of bone metastasis in breast cancers","volume":"10","author":"Yang Z","year":"2020","unstructured":"Yang Z, Yue Z, Ma X, Xu Z. Calcium homeostasis: a potential vicious cycle of bone metastasis in breast cancers. Front Oncol. 2020, 10:293. 10.3389\/fonc.2020.00293","journal-title":"Front Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy","volume":"99","author":"Hu MI","year":"2014","unstructured":"Hu MI, Glezerman IG, Leboulleux S, et al.. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014, 99:3144-52. 10.1210\/jc.2014-1001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06369-z","article-title":"Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer","volume":"33","author":"Wang R","year":"2022","unstructured":"Wang R, Renouf DA. Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer. Osteoporos Int. 2022, 33:1625-9. 10.1007\/s00198-022-06369-z","journal-title":"Osteoporos Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00171","article-title":"Incidence of medication-related osteonecrosis of the jaw in patients with breast cancer during a 20-year follow-up: a population-based multicenter retrospective study","volume":"43","author":"Brunner C","year":"2025","unstructured":"Brunner C, Arvandi M, Marth C, et al.. Incidence of medication-related osteonecrosis of the jaw in patients with breast cancer during a 20-year follow-up: a population-based multicenter retrospective study. J Clin Oncol. 2025, 43:180-8. 10.1200\/JCO.24.00171","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-64440-7","article-title":"Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management","volume":"14","author":"Tani M","year":"2024","unstructured":"Tani M, Hatano K, Yoshimura A, et al.. Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management. Sci Rep. 2024, 14:13451. 10.1038\/s41598-024-64440-7","journal-title":"Sci Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101148","article-title":"Hypercalcemia following discontinuation of denosumab therapy: a systematic review","volume":"15","author":"Horiuchi K","year":"2021","unstructured":"Horiuchi K, Kobayashi E, Mizuno T, Susa M, Chiba K. Hypercalcemia following discontinuation of denosumab therapy: a systematic review. Bone Rep. 2021, 15:101148. 10.1016\/j.bonr.2021.101148","journal-title":"Bone Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220940411","article-title":"Symptomatic hypocalcemia following a single dose of zoledronic acid in a patient with bone metastases secondary to breast cancer","volume":"27","author":"S\u00f6zel H","year":"2021","unstructured":"S\u00f6zel H, Yilmaz F. Symptomatic hypocalcemia following a single dose of zoledronic acid in a patient with bone metastases secondary to breast cancer. J Oncol Pharm Pract. 2021, 27:494-7. 10.1177\/1078155220940411","journal-title":"J Oncol Pharm Pract"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac621","article-title":"Treatment of hypercalcemia of malignancy in adults: an Endocrine Society clinical practice guideline","volume":"108","author":"El-Hajj Fuleihan G","year":"2023","unstructured":"El-Hajj Fuleihan G, Clines GA, Hu MI, et al.. Treatment of hypercalcemia of malignancy in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2023, 108:507-28. 10.1210\/clinem\/dgac621","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.20945\/2359-4292-2024-0035","article-title":"Rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review","volume":"68","author":"Schmitt L","year":"2024","unstructured":"Schmitt L, Theiler-Schwetz V, Sadoghi P, Trummer C, Pilz S. Rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review. Arch Endocrinol Metab. 2024, 68:e240035. 10.20945\/2359-4292-2024-0035","journal-title":"Arch Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luad133","article-title":"Denosumab-induced rebound hypercalcemia treated with bisphosphonates in a pediatric patient","volume":"1","author":"Gandolfi A","year":"2023","unstructured":"Gandolfi A, Shaaban S. Denosumab-induced rebound hypercalcemia treated with bisphosphonates in a pediatric patient. JCEM Case Rep. 2023, 1:luad133. 10.1210\/jcemcr\/luad133","journal-title":"JCEM Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.106.026","article-title":"Hypercalcemia following discontinuation of denosumab in adults: a case report","volume":"106","author":"Tondeur C","year":"2024","unstructured":"Tondeur C, Gombeir Y. Hypercalcemia following discontinuation of denosumab in adults: a case report. Endocrine Abstracts. 2024, 106:026. 10.1530\/endoabs.106.026","journal-title":"Endocrine Abstracts"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.11005\/jbm.24.803","article-title":"Incidence of hypercalcemia and vertebral fractures following denosumab withdrawal in lung cancer patients: a longitudinal cohort study","volume":"32","author":"Villanova M","year":"2025","unstructured":"Villanova M, Chou SH, Min L. Incidence of hypercalcemia and vertebral fractures following denosumab withdrawal in lung cancer patients: a longitudinal cohort study. J Bone Metab. 2025, 32:38-48. 10.11005\/jbm.24.803","journal-title":"J Bone Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06634-7","article-title":"Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis","volume":"30","author":"Ikesue H","year":"2022","unstructured":"Ikesue H, Doi K, Morimoto M, et al.. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis. Support Care Cancer. 2022, 30:2341-8. 10.1007\/s00520-021-06634-7","journal-title":"Support Care Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4317\/medoral.23324","article-title":"Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab vs. zoledronic acid: a systematic review and meta-analysis","volume":"25","author":"Limones A","year":"2020","unstructured":"Limones A, S\u00e1ez-Alcaide LM, D\u00edaz-Parre\u00f1o SA, Helm A, Bornstein MM, Molinero-Mourelle P. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab vs. zoledronic acid: a systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2020, 25:e326-36. 10.4317\/medoral.23324","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08687-w","article-title":"MASCC\/ISOO clinical practice statement: adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw","volume":"32","author":"Yarom N","year":"2024","unstructured":"Yarom N, Van Poznak CH, Epstein JB, Ottaviani G, Matsuda Y, Migliorati C, Elad S. MASCC\/ISOO clinical practice statement: adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw. Support Care Cancer. 2024, 32:547. 10.1007\/s00520-024-08687-w","journal-title":"Support Care Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.12788\/jcso.0166","article-title":"Prolonged zoledronic acid-induced hypocalcemia in hypercalcemia of malignancy","volume":"13","author":"Narechania S","year":"2015","unstructured":"Narechania S, Thiruchelvam N, Lokhande C, Kistangari G, Daw H. Prolonged zoledronic acid-induced hypocalcemia in hypercalcemia of malignancy. J Community Support Oncol. 2015, 13:374-7. 10.12788\/jcso.0166","journal-title":"J Community Support Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","volume":"51","author":"Body JJ","year":"2015","unstructured":"Body JJ, Bone HG, de Boer RH, et al.. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer. 2015, 51:1812-21. 10.1016\/j.ejca.2015.05.016","journal-title":"Eur J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-024-04478-3","article-title":"Recurrent severe hypocalcemia following chemotherapy regimen changes in advanced breast cancer: two case reports","volume":"18","author":"Yanase Y","year":"2024","unstructured":"Yanase Y, Bando H, Sato R, et al.. Recurrent severe hypocalcemia following chemotherapy regimen changes in advanced breast cancer: two case reports. J Med Case Rep. 2024, 18:150. 10.1186\/s13256-024-04478-3","journal-title":"J Med Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3190301","article-title":"Radiographic findings in patients with medication-related osteonecrosis of the jaw","volume":"2017","author":"Cardoso CL","year":"2017","unstructured":"Cardoso CL, Barros CA, Curra C, et al.. Radiographic findings in patients with medication-related osteonecrosis of the jaw. Int J Dent. 2017, 2017:3190301. 10.1155\/2017\/3190301","journal-title":"Int J Dent"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1259\/dmfr.20170323","article-title":"CT imaging features of antiresorptive agent-related osteonecrosis of the jaw\/medication-related osteonecrosis of the jaw","volume":"47","author":"Baba A","year":"2018","unstructured":"Baba A, Goto TK, Ojiri H, et al.. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw\/medication-related osteonecrosis of the jaw. Dentomaxillofac Radiol. 2018, 47:20170323. 10.1259\/dmfr.20170323","journal-title":"Dentomaxillofac Radiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/398791-hypercalcemia-of-malignancy-and-medication-related-osteonecrosis-of-the-jaw-following-denosumab-discontinuation-in-metastatic-breast-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:25:25Z","timestamp":1756279525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/398791-hypercalcemia-of-malignancy-and-medication-related-osteonecrosis-of-the-jaw-following-denosumab-discontinuation-in-metastatic-breast-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.91082","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}